Anti-Interferon alpha (IFNa) (Biotin)

Interferons (IFNs) appear early after viral infection locally and systematically to limit spread of viral infection. They also affect cell differentiation, growth, surface antigen expression and immunoregulation. There are three naturally occurring interferons: alpha, beta and gamma. Interferon alpha (IFN-alpha, IFNa) is also known as leukocyte interferon. B-lymphocytes are the predominant cellular producers of INF-alpha. IFN-alpha is derived from lymphoblastic tissue. IFN-alpha comprises a family of related, homologous proteins, each exhibiting a unique activity profile. The activities of the different IFN-alpha species on viruses can vary twenty fold or more. INF-alpha has a number of therapeutic applications in the treatment of various human cancers and diseases of viral origin. Recombinant IFN-alphas from both natural and synthetic genes bind to a common cell surface receptor and induce anti-viral activity in a variety of cell lines. When binding to discrete cell surface receptors on target cells, IFN-alpha induces rapid changes in Jak/Stat phosphorylation, which intiates the Jak/Stat signaling pathway. IFN-alpha signaling also involves production of DAG without an increased intracellular free calcium concentration and the subsequent activation of calcium-independent isoforms of PKC (beta and epsilon). All IFN-alpha signaling pathways lead to final alterations of gene expression, which mediate their pleiotropic biologic activities. IFN-alpha remains the most frequently used IFN for both research and clinical applications. It was first approved for combating malignancies. Anti-viral applications such as chronic Hepatitis B and C now make up the bulk of IFN sales. Different countries throughout the world have approved Hu-IFNa for different applications include: Chronic Hepatitis B, Chronic Hepatitis C, Hairy Cell Leukemia, Kaposi's Sarcoma (AIDS-related), Cutaneous T-cell Leukemia, Chronic Myeloid Leukemia, Renal Cell Carcinoma, Non-Hodgkin's Lymphoma, Adjuvant Therapy for Malignant Melanoma, Bladder Cell Carcinoma, Colon Carcinoma, Laryngeal Papillomatosis, Cervical Dysplasia, Condylomata Acuminata (Venereal Warts), Multiple Myeloma. Applications: Suitable for use in ELISA, Western Blot. Other applications have not been tested. Recommended Dilution: Western Blot: 0.5-3ug/ml, Optimal dilutions to be determined by the researcher. Storage and Stability: Store at 2-8°C. Do Not Freeze. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer., , Note: Applications are based on unconjugated antibody.